BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30027789)

  • 1. Midregional pro-atrial natriuretic peptide, an important member of the natriuretic peptide family: potential role in diagnosis and prognosis of cardiovascular disease.
    Idzikowska K; Zielińska M
    J Int Med Res; 2018 Aug; 46(8):3017-3029. PubMed ID: 30027789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
    Khan SQ; Dhillon O; Kelly D; Squire IB; Struck J; Quinn P; Morgenthaler NG; Bergmann A; Davies JE; Ng LL
    J Am Coll Cardiol; 2008 May; 51(19):1857-64. PubMed ID: 18466800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midregional pro atrial natriuretic peptide: a novel important biomarker for noise annoyance-induced cardiovascular morbidity and mortality?
    Hahad O; Wild PS; Prochaska JH; Schulz A; Lackner KJ; Pfeiffer N; Schmidtmann I; Michal M; Beutel M; Daiber A; Münzel T
    Clin Res Cardiol; 2021 Jan; 110(1):29-39. PubMed ID: 32306084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mid-regional pro-atrial natriuretic peptide levels in the elderly: clinical and prognostic implications, and comparison to B-type natriuretic peptides.
    Eggers KM; Venge P; Lind L
    Clin Chim Acta; 2013 Apr; 419():62-6. PubMed ID: 23415698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease.
    Ahluwalia N; Blacher J; Szabo de Edelenyi F; Faure P; Julia C; Hercberg S; Galan P
    Atherosclerosis; 2013 Jun; 228(2):478-84. PubMed ID: 23582589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
    Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
    J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.
    Sinning C; Ojeda F; Wild PS; Schnabel RB; Schwarzl M; Ohdah S; Lackner KJ; Pfeiffer N; Michal M; Blettner M; Munzel T; Kempf T; Wollert KC; Kuulasmaa K; Blankenberg S; Salomaa V; Westermann D; Zeller T
    Clin Res Cardiol; 2017 Jun; 106(6):401-410. PubMed ID: 28004184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical implications of current natriuretic peptide research.
    Sagnella GA
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):304-15. PubMed ID: 11967816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of midregional proatrial natriuretic peptide in patients with hemorrhagic stroke.
    Fischer M; Katan M; Morgenthaler NG; Seiler M; Müller B; Lackner P; Errath M; Helbok R; Pfausler B; Beer R; Schmutzhard E; Broessner G
    Cerebrovasc Dis; 2014; 37(2):128-33. PubMed ID: 24481415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes.
    Theilade S; Hansen TW; Goetze JP; Rossing P
    Am J Hypertens; 2015 Jun; 28(6):772-9. PubMed ID: 25468806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midregional pro-atrial natriuretic peptide in the general population/Insights from the Gutenberg Health Study.
    Tzikas S; Keller T; Wild PS; Schulz A; Zwiener I; Zeller T; Schnabel RB; Sinning C; Lubos E; Kunde J; Münzel T; Lackner KJ; Blankenberg S
    Clin Chem Lab Med; 2013 May; 51(5):1125-33. PubMed ID: 23183754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study.
    Pervez MO; Winther JA; Brynildsen J; Strand H; Christensen G; Høiseth AD; Myhre PL; Røysland R; Lyngbakken MN; Omland T; Røsjø H
    Biomarkers; 2018 Nov; 23(7):654-663. PubMed ID: 29733687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure.
    Kube J; Ebner N; Jankowska EA; Rozentryt P; Cicoira M; Filippatos GS; Ponikowski P; Doehner W; Anker SD; von Haehling S
    Int J Cardiol; 2016 Sep; 219():84-91. PubMed ID: 27288971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midregional pro-A-type natriuretic peptide for diagnosis and prognosis in patients with suspected acute myocardial infarction.
    Meune C; Twerenbold R; Drexler B; Balmelli C; Wolf C; Haaf P; Reichlin T; Irfan A; Reiter M; Zellweger C; Meissner J; Stelzig C; Freese M; Capodarve I; Mueller C
    Am J Cardiol; 2012 Apr; 109(8):1117-23. PubMed ID: 22257708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure.
    Seronde MF; Gayat E; Logeart D; Lassus J; Laribi S; Boukef R; Sibellas F; Launay JM; Manivet P; Sadoune M; Nouira S; Solal AC; Mebazaa A;
    Int J Cardiol; 2013 Oct; 168(4):3404-11. PubMed ID: 23684562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).
    O'Malley RG; Bonaca MP; Scirica BM; Murphy SA; Jarolim P; Sabatine MS; Braunwald E; Morrow DA
    J Am Coll Cardiol; 2014 Apr; 63(16):1644-53. PubMed ID: 24530676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MR-proANP level predicts new onset atrial fibrillation in patients with acute myocardial infarction.
    Karolina I; Michał K; Marzenna Z
    Biomarkers; 2020 Nov; 25(7):573-577. PubMed ID: 32972251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular biomarker midregional proatrial natriuretic peptide during and after preeclamptic pregnancies.
    Sugulle M; Herse F; Hering L; Mockel M; Dechend R; Staff AC
    Hypertension; 2012 Feb; 59(2):395-401. PubMed ID: 22184318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study.
    Daniels LB; Clopton P; Potocki M; Mueller C; McCord J; Richards M; Hartmann O; Anand IS; Wu AH; Nowak R; Peacock WF; Ponikowski P; Mockel M; Hogan C; Filippatos GS; Di Somma S; Ng L; Neath SX; Christenson R; Morgenthaler NG; Anker SD; Maisel AS
    Eur J Heart Fail; 2012 Jan; 14(1):22-31. PubMed ID: 22140234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.